26 June 2024 ORYZON announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb trial in Borderline Personality Disorder, at the 37th ECNP annual conference
14 June 2024 ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024
3 June 2024 ORYZON announces journal publication of final Phase IIa ALICE results with iadademstat in The Lancet Haematology
3-6 June 2024 BIO International Convention 2024 San Diego Convention Center, San Diego CA United States
29 May 2024 ORYZON selected as Associated Partner in the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)